Safety and Effectiveness of Physician-Modified Fenestrated and Branched Aortic Endografting for the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- 30 day survival
研究概览
简要总结
The primary clinical objective of this study is to evaluate the safety and effectiveness of a physician-modified, fenestrated and branched aortic endoprosthesis for the treatment of thoracoabdominal aortic aneurysms (TAAAs). The goal of the primary analysis is to demonstrate both the safety and effectiveness of using a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft as compared to previously published results of open surgical replacement of the aneurysmal aorta.
详细描述
This study is a prospective, two-arm, traditional feasibility study of a physician modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft base device in adult patients meeting traditional size criteria for open surgical treatment of thoracoabdominal aortic aneurysms (TAAAs). Patients meriting surgical treatment of their aneurysm that also meet inclusion and exclusion criteria will be eligible for enrollment. Patients will be followed for 5 years post procedure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 95 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Main Arm Inclusion Criteria:
- •Must be a man or woman 50 years of age or older by the date of informed consent
- •Must have a thoracoabdominal aortic aneurysm of any Crawford classification (extent I-V) that extends no more proximal than the left subclavian artery.
- •Must have an aneurysm size that meets standard indications for surgical repair (6.0 cm in maximum diameter in the descending thoracic aorta, or 5.5 cm in maximum diameter in the abdominal aorta)
- •Must be considered, in the judgement of the Investigator, to be a high- risk candidate for open surgical repair
- •Must commit to comply with the five-year study assessment schedule of events
- •Must have a non-aneurysm-related life expectancy, in the judgement of the Investigator, of greater than 2 years
- •Expanded Selection Inclusion Criteria:
- •Must be a man or woman 50 years of age or older by the date of informed consent
- •Must have a thoracic, thoracoabdominal, or abdominal aortic aneurysm that necessitates coverage of one or more visceral vessels (celiac, superior mesenteric, or renals) for establishment of proximal and/or distal seal. The aneurysm must not extend proximal to the left subclavian artery, or, in the setting of more proximal disease, that disease must have been previously treated.
- •Must have an aneurysm size that meets standard size indications for surgical repair (6.0 cm in maximum diameter in the descending thoracic aorta, or 5.5 cm in maximum diameter in the abdominal aorta); or, in the judgment of the Investigator, has aneurysm characteristics that portend a high risk of near-term rupture
- •In the setting of an aortic dissection the following criteria must exist:
- •Access into the true lumen from the groin and at least one supra-aortic trunk vessel
- •A sealing zone in the target aorta (or surgical graft) that is proximal to the primary dissection, such that a stent graft would be anticipated to seal off the dissection lumen
- •A sealing zone in the target supra-aortic trunk vessels that is distal to the dissection, anticipated to seal off the dissection lumen, or surgically created
- •A true lumen size large enough to deploy the device and still gain access into the target branches
- •Must be considered, in the judgement of the Investigator, to be a high-risk candidate for open surgical repair
- •Patient must be able to provide informed consent
- •Must commit to comply with the five-year study assessment schedule of events
- •Must have a non-aneurysm-related life expectancy, in the judgement of the Investigator, of greater than 2 years
排除标准
- •Aneurysm due to acute or chronic dissection, intramural hematoma, penetrating aortic ulceration, pseudoaneurysm, mycotic aneurysm, or traumatic transection
- •Ruptured or acutely symptomatic aortic aneurysm
- •Known connective tissue disorder
- •Imaging demonstrating any of the following:
- •Lack of 20 mm non-aneurysmal proximal seal zone (zone 3, or zone 2 with a carotid-subclavian bypass or transposition)
- •Lack of 15 mm non-aneurysmal distal seal zone(s) (aortic, common iliac, or external iliac)
- •Branch vessel target (renal, superior mesenteric, or celiac) < 5 mm or > 10 mm in average diameter
- •Untreated left subclavian artery stenosis or occlusion
- •Untreated unilateral or bilateral hypogastric artery occlusion
- •Signs that the inferior mesenteric artery is indispensable
- •Have branching, duplication, aneurysm, or untreatable stenosis of the celiac, superior mesenteric artery, or renal arteries that would preclude implantation of the investigational devices
- •Known allergies to stainless steel, PTFE, polyester, polypropylene, nitinol, or gold
- •History of anaphylaxis to contrast, with inability to prophylax appropriately.
- •Have uncorrectable coagulopathy
- •Have unstable angina
- •Have a body habitus that would inhibit X-ray visualization of the aorta
- •Have a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned ≤30 days of the endovascular repair
- •Known to be participating in any other clinical study which may affect performance of this - Ability to bear children
- •Contraindication to oral antiplatelet therapy
- •Prisoners or those on alternative sentencing
- •Known systemic infection with potential for endovascular graft infection
- •Anticipated need for MRI scanning within 3 months of insertion of investigational product
- •Candidate for repair under the Instructions for Use of a commercially available, FDA-approved endovascular graft
- •Can enroll in a manufacturer-sponsored clinical study at our institution or is willing and eligible to participate in a study with a manufacturer-made device at another institution.
- •Expanded Selection Exclusion Criteria:
- •Known or suspected mycotic aneurysm
- •Ruptured aneurysm with hemodynamic instability
- •Known connective tissue disorder
- •Imaging demonstrating any of the following:
- •Lack of 20 mm non-aneurysmal proximal seal zone (in either native aorta, elephant trunk graft, or aortic arch endograft)
- •Lack of 15 mm non-aneurysmal distal seal zone(s) (in either native aortoiliac vessels, prosthetic aortoiliac grafts, or aortoiliac endografts)
- •Branch vessel target (renal, superior mesenteric, or celiac) > 10 mm in average diameter
- •Known allergies to stainless steel, PTFE, polyester, polypropylene, nitinol, or gold
- •History of anaphylaxis to contrast, with inability to prophylax appropriately.
- •Have uncorrectable coagulopathy
- •Have a body habitus that would inhibit X-ray visualization of the aorta
- •Have a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned ≤ 30 days of the endovascular repair
- •Known to be participating in any other clinical study which may affect performance of this device
- •Ability to bear children
- •Contraindication to oral antiplatelet therapy
- •Prisoners or those on alternative sentencing
- •Known systemic infection with potential for endovascular graft infection
- •Anticipated need for MRI scanning within 3 months of insertion of investigational product
- •Candidate for repair under the Instructions for Use of a commercially available, FDA- approved endovascular graft
- •Can enroll in a manufacturer-sponsored clinical study at our institution or is willing and eligible to participate in a study with a manufacturer-made device at another institution
- •Other conditions or comorbidities that, in the opinion of the Investigator, would exclude the patient
研究组 & 干预措施
Main Arm
Use of a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
干预措施: Physician-modified aortic endograft (Device)
Expanded Access Arm
Use of a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal, thoracic, or abdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair in an expanded use population.
干预措施: Physician-modified aortic endograft (Device)
结局指标
主要结局
30 day survival
时间窗: 30 days
Percent of patients who survive 30 days following surgery
Major Adverse Events (MAE) at 30 days following surgery
时间窗: 30 days
Percent of patients who development major adverse events at 30-days following surgery including the following: * All-cause mortality * Loss of major organ or system function * Renal failure necessitating hemodialysis * Small or large bowel ischemia necessitating surgical or endovascular intervention * Hepatic ischemia necessitating surgical or endovascular intervention * Gastric ischemia necessitating surgical or endovascular intervention * Paraparesis * Paraplegia * Stroke (Modified Rankin Score of 2 or greater) * Myocardial infarction * Ventilator dependence \> 72 hours * Lower extremity ischemia necessitating surgical or endovascular intervention * Need for surgical or endovascular reintervention
Treatment success at 12 months following surgery
时间窗: 12 months
Percent of patients achieving treatment success through 1 year.
Technical success at 12 months following surgery
时间窗: 12 months
Technical success is assessed 12 months following surgery and is defined as a composite of: successful delivery, without need for unanticipated corrective intervention related to delivery; successful and accurate deployment at the intended implantation site; and successful withdrawal, without need for unanticipated correct intervention related to withdrawal.
次要结局
- Aneurysm rupture(Day of Surgery)
- Conversion to open repair(Day of Surgery)
- Paraparesis(Day of Surgery)
- Death during surgery(Day of Surgery)
- Major Adverse Events (MAEs)(At 30, 183 days; 1, 2, 3, 4 and 5 years)
- Treatment success(At 30, 183 days; 2, 3, 4 and 5 years)
- Technical success on the day of surgery(Day of Surgery)
- Lower extremity ischemia(Day of Surgery)
- Stroke(Day of Surgery)
- Paraplegia(Day of Surgery)
- Lower extremity compartment syndrome(Day of Surgery)
- Access site complication (Femoral or Iliac)(Day of Surgery)
- Survival rate(At 30, 183 days; 1, 2, 3, 4 and 5 years)
- Aneurysm-Specific Quality of Life Survey(At Screening, 30, 183 days; 2, 3, 4 and 5 years)
研究者
Bjoern D. Suckow
Associate Professor of Vascular Surgery
Dartmouth-Hitchcock Medical Center